Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
41 studies found for:    "familial adenomatous polyposis"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis
Conditions: Familial Adenomatous Polyposis;   Duodenal Neoplasms;   Duodenal Polyps
Interventions: Drug: Celecoxib;   Drug: Ursodeoxycholic acid;   Drug: Placebo
2 Active, not recruiting Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)
Conditions: Familial Adenomatous Polyposis;   Colorectal Cancer
Interventions: Behavioral: Web-Based Multimedia Intervention;   Behavioral: Questionnaire
3 Recruiting Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
Condition: Familial Adenomatous Polyposis
Interventions: Drug: Calcumin (Curcumin);   Other: Risk Factor Questionnaire;   Other: Blood samples;   Other: Biopsies (Sigmoidoscopy);   Other: Biopsies (Upper endoscopy)
4 Completed
Has Results 		Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA
Conditions: Familial Adenomatous Polyposis Coli;   FAP
Interventions: Drug: Eicosapentanoic Acid (EPA);   Procedure: Endoscopy;   Procedure: Biopsies taken;   Drug: Placebo
5 Terminated
Has Results 		Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
Condition: Familial Adenomatous Polyposis (FAP)
Interventions: Drug: Celecoxib;   Other: Routine Medical Care
6 Recruiting Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Condition: Familial Adenomatous Polyposis
Interventions: Drug: Eflornithine plus Sulindac;   Drug: Eflornithine and Placebo;   Drug: Sulindac and Placebo
7 Withdrawn Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients
Condition: Familial Adenomatous Polyposis
Intervention: Drug: curcumin
8 Completed Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)
Condition: Familial Adenomatous Polyposis
Interventions: Drug: Lyophilized Black Raspberries;   Drug: Placebo
9 Recruiting Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis
Condition: FAP-Familial Adenomatous Polyposis
Intervention: Drug: Erythromycin
10 Not yet recruiting Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version
Condition: FAP-Familial Adenomatous Polyposis
Intervention: Drug: Erythromycin
11 Recruiting Curcumin in Treating Patients With Familial Adenomatous Polyposis
Condition: Familial Adenomatous Polyposis
Interventions: Other: Placebo;   Other: Laboratory Biomarker Analysis;   Drug: Curcumin
12 Withdrawn A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Condition: Familial Adenomatous Polyposis
Interventions: Drug: Eflornithine plus Sulindac;   Drug: Eflornithine plus Placebo;   Drug: Sulindac plus Placebo
13 Recruiting Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients
Conditions: Colitis,Ulcerative;   Adenomatous Polyposis Coli;   Reservoir, Ileoanal
Intervention:
14 Terminated
Has Results 		Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
Conditions: Colorectal Cancer;   Familial Adenomatous Polyposis
Interventions: Drug: Celecoxib;   Other: Placebo;   Drug: eflornithine;   Other: Laboratory biomarker analysis;   Other: Questionnaire administration
15 Recruiting Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW
Condition: Adenomatous Polyposis Coli
Interventions: Drug: Bevacizumab-IRDye800CW;   Device: Near infrared fluorescence endoscopy platform
16 Recruiting The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study
Condition: Familial Adenomatous Polyposis
Intervention: Drug: metformin
17 Active, not recruiting A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Condition: Adenomatous Polyposis Coli
Interventions: Drug: Erlotinib;   Drug: Sulindac;   Drug: Placebo A;   Drug: Placebo B
18 Terminated
Has Results 		Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
Condition: Adenomatous Polyposis Coli
Interventions: Drug: Celecoxib;   Drug: Placebo
19 Terminated A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)
Condition: Adenomatous Polyposis Coli
Interventions: Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks;   Drug: Comparator: placebo / Duration of Treatment: 24 weeks
20 Recruiting Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes
Conditions: Familial Adenomatous Polyposis;   Map Syndrome;   Lynch Syndrome;   Hnpcc;   Colorectal Cancer
Intervention: Other: Epi proColon Testing
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Indicates status has not been verified in more than two years